The Amazing Race 2022 Update: Next-Gen Immuno-Oncology Edition

The Amazing Race 2022 Update: Next-Gen Immuno-Oncology Edition

Eric Blouin Eric Blouin

Eric Blouin

发布日期: 2022年3月6日
+ 关注

The first update to our inaugural 2021 Point-of-View, this article will provide you with a summary of all of the developments since that time, as well as our analysis of the potential impact on the oncology landscape. Who is most likely to give HCPs and Patients novel breakthrough treatment options - TIGIT or LAG3?

Please go to https://www.ipsos.com/en-us/knowledge/consumer-shopper/The-Amazing-Race-Next-Gen-Immuno-Oncology-Edition-paper to read the full article and download the PDF.

#oncology #pharmaceutical #biotech # cancer #immuno-oncology #TIGIT #LAG3

要查看或添加评论，请登录

Eric Blouin的更多文章

  • Year in Review: 2024 Oncology FDA Approvals
    2024年12月20日

    Year in Review: 2024 Oncology FDA Approvals

    We are fast approaching the close of 2024. As a result, I was curious to see how this year stacked up to prior ones…

  • Can Comprehensive Genomic Profiling change the game?
    2022年9月19日

    Can Comprehensive Genomic Profiling change the game?

    It was my great pleasure to team up with t Ayse Levent, Ipsos' Molecular Diagnostic expert, to bring you this point of…

  • Finally, some good news for Gilead’s oncology aspirations
    2022年9月9日

    Finally, some good news for Gilead’s oncology aspirations

    Coming out of ASCO 2022 this past June, Gilead’s $21B acquisition of Immunomedics & Trodelvy in 2020 seemed like…

  • The KEY to Survival
    2019年6月6日

    The KEY to Survival

    Reflecting on this past ASCO, and the ‘big’ stories that came out of it in many tumor types (including lung, prostate…

社区洞察

其他会员也浏览了